Tumor proteases and inhibitors have been associated with paradoxical effects on tumor progression in preclinical and clinical settings. We previously reported that urokinase (uPA) overexpression delays tumor progression in mammary cancer. This study aimed to determine the role of plasminogen activator inhibitor-1 (PAI-1) on uPA's paradoxical in vivo effects. Using syngeneic murine models, we found that stable uPA overexpression promoted in vivo growth of colon tumors (MC-38) naturally expressing high PAI-1, while growth inhibition was observed in renal tumors (RENCA) expressing lower PAI-1 levels. In murine mammary carcinoma (4T1), uPA overexpression shifted the uPA/PAI-1 balance in favor of the protease, resulting in significantly reduced tumor growth and metastases in vivo. Conversely, increased tumor progression was observed in stable PAI-1 overexpressing 4T1 tumors, compared to uPA overexpressing and control tumors.
1 balance in favor of the protease, resulting in significantly reduced tumor growth and metastases in vivo. Conversely, increased tumor progression was observed in stable PAI-1 overexpressing 4T1 tumors, compared to uPA overexpressing and control tumors.
These effects were associated with down regulation of metastases promoting genes in uPA overexpressing tumors, such as metalloproteinases, CXCL-1, c-Fos, integrin α-5, VEGF-A, PDGF-α and IL-1β. In PAI-1 overexpressing tumors, many of the above genes were upregulated. PAI-1 overexpressing tumors had increased total and new tumor microvessels, and increased tumor cell proliferation, while the opposite effects were found in uPA overexpressing tumors. Finally, PAI-1 down-regulation led to significant inhibition of 4T1 tumor growth and metastases in vivo. In conclusion, uPA's dual effects on tumor progression occur in the context of its interactions with endogenous PAI-1 expression. Our studies uncover novel mechanisms of in vivo tumor control by modulation of the balance between tumor proteases and inhibitors, which may be exploited therapeutically.
INTRODUCTION
Tumor proteases have long been associated with tumor invasion, angiogenesis and metastases (1, 2) . It is widely accepted that urokinase (uPA), a member of the plasminogen activator (PA) system, is tumor promoting and associated with an aggressive tumor phenotype (1, 3) . Tumor uPA expression is associated with shorter disease free and overall survival in patients with early stage breast cancer (4) (5) (6) (7) , and has been proposed as a potential target for antitumor strategies (1, 3, (8) (9) (10) . Paradoxically, overexpression of plasminogen activator inhibitor-1 (PAI-1), the endogenous inhibitor of uPA, is a clinically validated negative prognostic factor in breast and other cancers (6, 11, 12) . PAI-1 has been shown to be essential for angiogenesis and tumor progression (13) (14) (15) . PAI-1 promotes angiogenesis through interaction with vitronectin (16) and by direct inhibition of proteases (14) .
We have previously reported that PAs induce antiangiogenic effects in vitro and in vivo (17) . We also demonstrated that overexpression of uPA paradoxically delayed tumor growth, metastases, and improved survival in a syngeneic, immunocompetent mammary cancer model, (18) . Urokinase's tumor delaying effects were due to its protease activity, as tumors overexpressing proteolytically inactive uPA mutants were not associated with antitumor effects. On the other hand, several matrix metalloproteinases are associated with protective -rather than promoting-effects on in vivo tumor models (19) . Proteases have been implicated in the generation of antiangiogenic peptides, such as angiostatin, endostatin and tumstatin (20) (21) (22) .
The above observations suggest that urokinase can be both tumor promoting and protective and further support the notion that non-specific inhibition of proteases may not necessarily prevent tumor progression (14, 19, 23) . They also underscore the need to reevaluate current concepts on the role of uPA in cancer progression. The mechanisms of uPA mediated tumor growth delay have not yet been characterized.
In this report, we provide experimental evidence that the tumor promoting or delaying effects of urokinase depend on its dynamic balance with tumor PAI-1. We also provide insight into the in vivo molecular changes that may mediate uPA's tumor delaying effects, and demonstrate the antitumor and antimetastatic effects of in vivo PAI-1 inhibition.
MATERIALS AND METHODS
Cell culture. Murine mammary carcinoma 4T1 cell line, colon carcinoma MC38 cell line, renal cancer RENCA cell line, and 293T were obtained from ATCC (Manassas, VA). Cells were grown in DMEM medium containing 10% FBS at 37°C and 5% CO 2 . Generation of stable PAI-1 knock down 4T1 cell lines. Lentiviral vectors (pGIPZ) containing shRNA against murine PAI-1 and non-silencing controls were purchased from OpenBiosystems (Huntsville, AL). Lentiviral packaging and transduction into 4T1 cells were performed following the manufacturer's recommendations. Ninety-six hours after transduction, stable PAI-1 shRNA expressing cells were selected in 10 µg/ml puromycin (Sigma-Aldrich, St. Louis, MO). PAI-1 known down was confirmed by real time PCR and determination of protein levels by ELISA.
Generation
Western Blot. Constructs for uPA wild type and empty vector were transiently transfected into 293T cells as described above. After 48h, the maintenance culture medium was replaced with Opti-Medium. After 48 h of continued incubation, the conditioned medium was collected and subsequently concentrated using the Centricon-10 filter units (Amicon, Bedford, MA). Protein concentrations were determined by using the BCA Protein Assay Kit (Pierce, Rockford, IL). Proteins were separated by SDS-polyacrylamide gel electrophoresis on 10% gels (Bio-Rad, Hercules, CA) under nonreducing and reducing conditions, transferred to nitrocellulose membrane (Amersham Biosciences, Piscataway, NJ), and immunoblotted with a monoclonal antibody against mouse uPA (sc-59727 Santa Cruz Biotechnology, Santa Cruz, CA) at 1:1000 dilution). After the blots were washed by TBST, HRP conjugated anti-mouse second antibody at 1:2000 dilution (Cell signaling, Danvers, MA) was applied, and the peroxidase activity was revealed with the enhanced chemiluminescence system (Amersham Bioscience, Piscataway, NJ) according to the manufacturer's instructions.
Quantification of uPA and PAI-1. Murine uPA and PAI-1 total protein and levels of active protein were determined in the conditioned medium (48 hours) of RENCA, MC38 and 4T1 clones by using a total or active murine uPA and PAI-1 ELISA kit, following the manufacturer's recommendations (Molecular Innovations, Novi, MI). uPA proteolytic activity was assessed using a colorimetric urokinase activity kit (Chemicon, Tremecula, CA), as previously reported (18) .
In vitro proliferation assay. One thousand cells per well were plated in 96-well plates in complete medium and incubated at 37 °C. Cell proliferation was determined by WST-1 proliferation reagent (Roche, Indianapolis, IN), as previously reported (18) .
Soft agar assay. Soft agar assay was performed using cell transformation detection kit (Millipore, Billerica, MA) as previously described (24) . Briefly, 4T1 cells (2500 cells per well) were plated in DMEM plus 10% FBS in 0.4% agar on top of a 0.8% base agar layer in 6 well plate. After 2 weeks, colony formation was quantified with a cell quantification solution (Millipore, Billerica, MA) for 3 hours at 37°C, followed by spectrophotometer reading at OD490. (18) . Tumor volume was measured every 3 days and calculated using the stan-dard formula (width 2 × length × 0.52). In the experiments involving 4T1 tumors, mice were followed until day 34 when they were sacrificed. Lungs were removed and fixed in Bouin's solution, and surface lung metastases were analyzed (26) . In an additional experiment, 4T1 cells (10 5 cells) were implanted into BALB/c mice (12 mice per group). Tumor volume was measured as above until day 21, when tumors were resected and mice continued to be followed. At day 42, they were sacrificed and lungs were resected (randomly) from five mice per group. Lungs were fixed (10% neutral-buffered formalin), embedded in paraffin, sectioned (5-μm slices, 400 μm apart), and stained with hematoxylin and eosin. Magnified (×20) lung nodules were counted. were performed in triplicate and repeated twice, unless otherwise specified. Differences in means from the in vitro experiments were compared by using the Student's t test and
Wilcoxon rank-sum test. Differences were considered statistically significant at P<.05.
Differences of in vivo tumor growth and lung metastases among three or more groups were analyzed by one-way analysis of variance. Pairwise comparisons were performed using the Tukey-Kramer method. All statistical tests were two-sided.
RESULTS
Urokinase overexpression is associated with tumor promoting or suppressing effects in different syngeneic models: role of endogenous PAI-1 expression. We have previously reported that uPA overexpression delays in vivo tumor progression in a syngeneic mammary cancer model (18) . To extend the above findings, we generated stably uPA however, in the CM of MC-38-uPA cells, levels of active uPA were significantly lower than their RENCA counterparts (p < 0.0001; fig. 1 . B). This was associated with higher uPA proteolytic activity (chromogenic assay) in the RENCA uPA CM compared to MC-38-uPA CM (Fig. S.1 
. C, E).
This suggested that uPA's activity in MC-38-uPA was inhibited by a factor in the CM.
Because PAI-1 is the most relevant endogenous uPA inhibitor (1), levels of the inhibitor were measured in RENCA-uPA and MC-38-uPA's CM. PAI-1 expression in MC 38 cells was significantly higher (~ 45-fold), compared to RENCA (Fig. 1 . D, vs. 1. C; p= 0.0003).
Levels of uPA receptor were assessed in the uPA overexpressing RENCA and MC-38 cells, and were not found to be significantly changed, compared to controls (Fig. S. 1. D,   F ). In vitro growth rate was not different between uPA overexpressing RENCA ( Fig. 1. E) and MC-38 cells (Fig. 1. F control (EV) cells, total and active PAI-1 levels predominated over uPA (Fig. 2. A, B) .
In 4T1-uPA cells, levels of urokinase predominated over PAI-1 (Fig. 2. A, B ) -similar to RENCA-uPA tumors-. Conversely, in 4T1-PAI-1 cells, levels of total and active PAI-1 were significantly increased ( Fig. 2. A, B) , further shifting the balance towards the inhibitor, a condition similar to MC-38-uPA tumors. uPA proteolytic activity (chromogenic assay) was noticeable increased in the uPA overexpressing, but decreased in the PAI-1 overexpressing tumors, compared to controls (Fig. S. 2. A) .
In vitro growth was comparable in both uPA and PAI-1 overexpressing cells, compared to controls (p= NS; Fig. 2 . C). PAI-1 over-expression significantly inhibited cell migration ( Fig. 2 . D) and invasion ( Fig. 2 . E), while uPA overexpression significantly increased migration and invasion in vitro, in agreement with previous reports (29, 30 ). Anchorage independent cell growth in both uPA and PAI-1 4T1 cells was similar to control cells ( Fig. 2. F) . Levels of uPA receptor were not significantly changed in the uPA overexpressing 4T1 cells, compared to controls (Fig. S. 2 . B).
The above 4T1 clones were orthotopically implanted in BALB/C mice for assessment of tumor progression phenotypes. uPA overexpressing 4T1 tumors had decreased tumor growth, while 4T1-PAI-1 tumor growth was significantly higher, compared to controls (Fig. 3. A) , with a significant difference in tumor weight (day 34) between the uPA and PAI-1 overexpressing tumors ( Fig. 3.B; p=0.01). At this time point, mice bearing 4T1-uPA tumors had significantly decreased (p=0.016), while 4T1-PAI-1 tumors had significantly increased (p< 0.0001) lung metastases compared to controls.
To further investigate the anti-metastatic effects of uPA or PAI-1 overexpression in the absence of a primary tumor, additional tumor bearing mice had their mammary tumors removed at day 21 after implantation and were followed until day 42, when analysis of lung metastases was conducted. Again, mice in the 4T1-uPA group had significantly less metastatic nodules (Fig. S. 2.D) , compared to the 4T1-PAI-1 group, even in the absence of primary tumors. Primary tumor growth (day 21) was also decreased in the 4T1-uPA group than in tumors overexpressing PAI-1 (Fig. S. 2 
.C).

Correlation between tumor progression phenotypes and changes in gene expression in vivo.
To gain insight into the molecular mechanisms of uPA's in vivo antitumor effects, total RNA was isolated from additional (3 per group) 4T1-uPA tumors and controls at day 7-8 after implantation, for analysis of gene expression. Significantly regulated genes were analyzed in the context of their involvement with pathways relevant for tumor progression and metastases. Urokinase overexpressing tumors had a statistically significant down regulation of genes involved in pathways related to extracellular matrix remodeling, adhesion, VEGF-A, WNT, TGF-β, hypoxia, and EMT, compared to controls (Table I) .
To validate the above findings, qRT-PCR analysis of selected genes was performed. In addition, total RNA from 4T1-PAI-1 (7-8 days old) tumors was isolated, for comparative analysis. Analysis demonstrated that many tumor promoting genes (MMP-12, CXCL-1,
JAG-1, endothelin-1, ADAMTS12, c-Fos, integrin alpha-5, VEGF-A and IL-1β) were
down regulated in the uPA overexpressing tumors, while they were upregulated or unchanged in the PAI-1 group, (Fig. 4) . MMP-9, MMP-10 and MMP-13 were downregulated in both the uPA and PAI-1 overexpressing groups, albeit down-regulation was more pronounced in the 4T1-uPA compared to the 4T1-PAI-1 groups (Fig. 4) . 
Urokinase mediated gene downregulation occurs in vivo but
PAI-1 down-regulation inhibits in vivo primary tumor growth and metastases. Next,
we investigated the effects of PAI-1 inhibition on in vivo tumor progression. PAI-1 k/d 4T1 cell lines were generated, and down-regulation of (total and active) PAI-1 was confirmed ( Fig. 6. A, B) . PAI-1 inhibition led to an increase in active uPA levels ( Fig. 6. A,   B ). While in vitro proliferation (not shown) and anchorage independent growth was unchanged ( Fig. 6. D) , PAI-1 down-regulation led to enhanced migration and invasion, compared to controls (Fig. 6 . C). After implantation of the stable cell lines into BALB/C mice, we observed that PAI-1 k/d tumors were associated with a significant inhibition of primary tumor growth ( Fig. 6 . E), as well as lung metastases at day 34 ( Fig. 6. F) .
DISCUSSION
The understanding of the role of tumor proteases and inhibitors in cancer biology is evolving. Contrary to the established paradigm that proteases are exclusively tumor promoters, we and others have demonstrated that they can negatively regulate tumor progression (18, 19, 31, 32) . In this report, we provide experimental evidence supporting the 
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